Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer

The new combination of ifosfamide and vinorelbine wasevaluated in a phase II study of patientswith metastatic breast cancer. All the patients hadevaluable or measurable lesions resistant to the combinationof cyclophosphamide, epidoxorubicin and 5-fluorouracil. Out of 25patients entered the trial, 7 achieved an objectiveresponse (28%) (95% C.I. 12–49.3).Ten patients (40%) experienced stable disease andthe remaining patients (30%) progressive disease.The median time to progression was 4 months (range 2–12 +).The activity of the ifosfamide-vinorelbine combinationhas been demonstrated and the toxicity was acceptable.